Calcium Channel Blocker Flops in Parkinson’s Disease Trial

Calcium Channel Blocker Flops in Parkinson’s Disease Trial

Publication date: May 03, 2019

No significant difference was seen after 36 months in average Unified Parkinson Disease Rating Scale (UPDRS) Part I-III scores measured in the ON state for patients receiving isradipine (DynaCirc) at 10 mg daily versus placebo (treatment effect 0. 27 points, 95% CL -2. 5 to 3. 0, P=0. 85), reported Tanya Simuni, MD, of the Northwestern University Feinberg School of Medicine, and colleagues.

“The study was based on solid mechanistic rationale, partly on animal data, and epidemiological data supporting that this mechanism is relevant to this human disease,” Simuni told MedPage Today.

In 2007, findings from a study published in Nature led by James Surmeier, PhD, at Northwestern, linked the death of dopaminergic neurons — the hypothesized the cause of Parkinson’s disease — with the excitement of calcium channels in these cells.

The initial studies were followed by a 2013 phase II trial conducted by the Parkinson’s Study group, STEADY-PD, which established 10 mg of controlled-release isradipine as the maximum tolerable dosage for patients with early Parkinson’s disease; with fewer than 30 patients in each study arm, it was not powered to demonstrate efficacy.

“What this study demonstrates is that this particular drug at this particular dose does not have the benefit of slowing progression of early Parkinson’s disease,” she said.

Concepts Keywords
Alabama S
Antagonist Parkinson s disease
Birmingham Organic compounds
Calcium Chemical compounds
Calcium Channel Calcium channel blockers
Calcium Channel Blocker Chemistry
Controlled Release Dihydropyridines
Dopamine Ion channels
Dopaminergic Isradipine
Epidemiological Electrophysiology
Motor Disability Calcium channels
Nature Neuron
Neurodegenerative Parkinson
Neurology Felodipine
Neurons
Neuroprotective
Parkinson
Pathology
Phase III
PhD
PHILADELPHIA
Placebo
Rodent
Stress

Semantics

Type Source Name
drug DRUGBANK Spinosad
drug DRUGBANK Dopamine
gene UNIPROT ARMC9
gene UNIPROT AKR1A1
pathway BSID Release
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Calcium
gene UNIPROT SMIM10L2B
gene UNIPROT SMIM10L2A
gene UNIPROT PDC
disease MESH death
drug DRUGBANK Felodipine
gene UNIPROT FURIN
disease MESH complications
drug DRUGBANK Dihydrotachysterol
drug DRUGBANK Isradipine
disease DOID Parkinson Disease
disease MESH Parkinson Disease

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *